Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Breast Neoplasms 83Colorectal Neoplasms 52Stomach Neoplasms 42Pancreatic Neoplasms 42Lung Neoplasms 41Rectal Neoplasms 38Neoplasm Metastasis 36Neoplasms 33Esophageal Squamous Cell Carcinoma 32Esophageal Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 23Ovarian Neoplasms 23Triple Negative Breast Neoplasms 21Nasopharyngeal Carcinoma 20Recurrence 18Leukemia, Myeloid, Acute 18Colonic Neoplasms 18Uterine Cervical Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Small Cell Lung Carcinoma 15Glioblastoma 15Lymphoma 12Prostatic Neoplasms 11Fallopian Tube Neoplasms 11Carcinoma, Squamous Cell 11Brain Neoplasms 11Sarcoma 10NSCLC 9

Interventions

Immunotherapy 2anlotinib 1Radiotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced Non-small Cell Lung Cancer × Drug Therapy × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡